Cargando…

Respiratory Abnormalities in Parkinson’s Disease: What Do We Know from Studies in Humans and Animal Models?

Parkinson’s disease (PD) is the second most common progressive neurodegenerative disease characterized by movement disorders due to the progressive loss of dopaminergic neurons in the ventrolateral region of the substantia nigra pars compacta (SNpc). Apart from the cardinal motor symptoms such as ri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaczyńska, Katarzyna, Orłowska, Magdalena Ewa, Andrzejewski, Kryspin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8998219/ https://www.ncbi.nlm.nih.gov/pubmed/35408858 http://dx.doi.org/10.3390/ijms23073499

Ejemplares similares

Serotonergic system in hypoxic ventilatory response in unilateral rat model of Parkinson’s disease
por: Andrzejewski, Kryspin, et al.
Publicado: (2017)

L-DOPA Improves Ventilation but Not the Ventilatory Response to Hypercapnia in a Reserpine Model of Parkinson’s Disease
por: Jampolska, Monika, et al.
Publicado: (2023)

Respiratory pattern and phrenic and hypoglossal nerve activity during normoxia and hypoxia in 6-OHDA-induced bilateral model of Parkinson’s disease
por: Andrzejewski, Kryspin, et al.
Publicado: (2020)

Deficiency of Biogenic Amines Modulates the Activity of Hypoglossal Nerve in the Reserpine Model of Parkinson’s Disease
por: Jampolska, Monika, et al.
Publicado: (2021)

Quasicrystals: What do we know? What do we want to know? What can we know?
por: Steurer, Walter
Publicado: (2018)

Intracerebroventricular Neuropeptide FF Diminishes the Number of Apneas and Cardiovascular Effects Produced by Opioid Receptors’ Activation
por: Wojciechowski, Piotr, et al.
Publicado: (2020)

What do we know and when do we know it?
por: Nicholls, Anthony
Publicado: (2008)

Presbyopia: What We Do Know and What We Do Not Know in 2022
por: Grzybowski, Andrzej, et al.
Publicado: (2023)

Biogenic Silver Nanoparticles: What We Know and What Do We Need to Know?
por: Rai, Mahendra, et al.
Publicado: (2021)

Vaginal Aging—What We Know and What We Do Not Know
por: Szymański, Jacek K., et al.
Publicado: (2021)

Role of the Eye in Transmitting Human Coronavirus: What We Know and What We Do Not Know
por: Sun, Chuan-bin, et al.
Publicado: (2020)

Colonization and infection of the respiratory tract: What do we know?
por: Robinson, Joan
Publicado: (2004)

Transmission of Ebola Viruses: What We Know and What We Do Not Know
por: Osterholm, Michael T., et al.
Publicado: (2015)

Multimorbidity: What do we know? What should we do?
por: Navickas, Rokas, et al.
Publicado: (2016)

What we do and do not know about managing respiratory disease in pregnancy
por: Kent, Brian D.
Publicado: (2022)

Hypoxic and Hypercapnic Responses in Transgenic Murine Model of Alzheimer’s Disease Overexpressing Human AβPP: The Effects of Pretreatment with Memantine and Rivastigmine
por: Andrzejewski, Kryspin, et al.
Publicado: (2022)

Animal Coronaviruses and SARS-COV-2 in Animals, What Do We Actually Know?
por: Bonilauri, Paolo, et al.
Publicado: (2021)

Cerebrospinal fluid circulation: What do we know and how do we know it?
por: Khasawneh, Ahmad H, et al.
Publicado: (2018)

Metal wear particles: What we know, what we do not know, and why
por: Billi, Fabrizio, et al.
Publicado: (2009)

Mechanisms of atrial fibrillation in athletes: what we know and what we do not know
por: Guasch, E., et al.
Publicado: (2018)

What Do We Know about Nociplastic Pain?
por: Bułdyś, Kacper, et al.
Publicado: (2023)

Ticks and Tularemia: Do We Know What We Don't Know?
por: Zellner, Briana, et al.
Publicado: (2019)

Middle East Respiratory Syndrome Coronavirus: What Do We Know?
por: Sousou, Jeanann
Publicado: (2015)

Cardiac surgery and the coronavirus disease 2019 pandemic: What we know, what we do not know, and what we need to do
por: Bakaeen, Faisal G., et al.
Publicado: (2020)

Investigating emotions in Parkinson's disease: what we know and what we still don't know
por: Sotgiu, Igor, et al.
Publicado: (2013)

What Do We Know about Theory of Mind Impairment in Parkinson’s Disease?
por: Trompeta, Clara, et al.
Publicado: (2021)

COVID-19 and Parkinson’s Disease: What Do We Know So Far?
por: Artusi, Carlo Alberto, et al.
Publicado: (2021)

Eosinophilic Esophagitis—What Do We Know So Far?
por: Wąsik, Jakub, et al.
Publicado: (2023)

Management of T1 Urothelial Carcinoma of the Bladder: What Do We Know and What Do We Need To Know?
por: Gershman, Boris, et al.
Publicado: (2015)

Thymic neuroendocrine neoplasms—what we know, what we don’t know, and what to do about it
por: Lang, Matthias, et al.
Publicado: (2023)

Dyskinesias after neural transplantation in Parkinson's disease: what do we know and what is next?
por: Politis, Marios
Publicado: (2010)

Endomorphin-2- and Neurotensin- Based Chimeric Peptide Attenuates Airway Inflammation in Mouse Model of Nonallergic Asthma
por: Russjan, Ewelina, et al.
Publicado: (2019)

The Catecholaldehyde Hypothesis for the Pathogenesis of Catecholaminergic Neurodegeneration: What We Know and What We Do Not Know
por: Goldstein, David S.
Publicado: (2021)

Microbiome in Multiple Sclerosis: Where Are We, What We Know and Do Not Know
por: Boziki, Marina Kleopatra, et al.
Publicado: (2020)

The risk of viral transmission in feed: What do we know, what do we do?
por: Dee, Scott A., et al.
Publicado: (2020)

Experimental subjects do not know what we think they know
por: Field, Jared M., et al.
Publicado: (2020)

Health Statistics in Australia: What We Know and Do Not Know
por: Madden, Richard, et al.
Publicado: (2022)

Equine Crofton Weed (Ageratina spp.) Pneumotoxicity: What Do We Know and What Do We Need to Know?
por: Shapter, Frances Marie, et al.
Publicado: (2023)

The cancer-obesity connection: what do we know and what can we do?
por: Riboli, Elio
Publicado: (2014)

Isolated Nocturnal Hypertension: What Do We Know and What Can We Do?
por: Tadic, Marijana, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ig4pq6dudf4uc15un2vmvahl2s